Webinar Date/Time: Thursday, December 5th, 2024 at 11:00 AM EST
Overcome Bioconjugate Development Challenges and Accelerate CMC Timelines.
Register Free: https://www.biopharminternational.com/bp_w/bioconjugate-development
Event Overview:
The bioconjugate field is undergoing rapid evolution, and the development of new bioconjugate structures requires intricate, multifaceted approaches that encompass carrier molecules, linkers, and small molecule drugs. This complexity presents significant challenges in the analytical development of bioconjugates, including the need to assess linker-payload stability, conjugation heterogeneity (in terms of site and ratio), and process-related impurities, as well as to develop specialized assays to monitor the conjugation process. Moreover, a critical aspect is the efficient development of analytical methods tailored to the diversity of bioconjugates.
This presentation delves into the development of physicochemical and biochemical analysis methods for various types of bioconjugates, presenting an integrated analytical strategy to address development hurdles and accelerate the CMC timeline.
Key Learning Objectives:
Who Should Attend:
Speaker:
Dr. Zhiguo Li
Executive Director
WuXi XDC
Dr. Zhiguo Li has 16+ years of biopharmaceutical industry experience in analytical chemistry and pharmaceutical science, including 9+ years at WuXi XDC and WuXi Biologics, 3 years at Novo Nordisk, and 2+ years at Abbott. He received his Bachelor’s Degree from Shandong University and Ph.D. from University of the Pacific, California.
Register Free: https://www.biopharminternational.com/bp_w/bioconjugate-development
EXO Biologics and ExoXpert Reach Two Critical Milestones that Advance Exosomes
December 3rd 2024EXO Biologics and its subsidiary, ExoXpert, have received GMP certification of a European exosomes manufacturing facility and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.